Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brigitte C Widemann

Showing results (191-200 of 203) with videos related to

Pageof 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2024
Update on Pediatric Cancer Surveillance Recommendations for Patients with Neurofibromatosis Type 1, Noonan Syndrome, CBL Syndrome, Costello Syndrome, and Related RASopathiesMelissa R Perrino, Anirban Das, Sarah R Scollon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2024
Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA FragmentomicsR Taylor Sundby, Jeffrey J Szymanski, Alexander C Pan, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 2, 2018
Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrumVictoria E R Parker, Kim M Keppler-Noreuil, Laurence Faivre, et al.
Neuro-Oncology|July 5, 2022
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensusPeter M K de Blank, Andrea M Gross, Srivandana Akshintala, et al.
American Journal of Medical Genetics. Part A|March 26, 2019
First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeuticsKatherine A Rauen, Abeer Alsaegh, Shay Ben-Shachar, et al.
American Journal of Medical Genetics. Part A|September 27, 2014
Update from the 2013 International Neurofibromatosis ConferenceScott R Plotkin, Anne C Albers, Dusica Babovic-Vuksanovic, et al.
Nature Medicine|January 14, 2021
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trialMichael J Fisher, Chie-Schin Shih, Steven D Rhodes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2023
The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric CancerJoseph A Flores-Toro, Subhashini Jagu, Gregory T Armstrong, et al.
Nature Medicine|April 16, 2026
Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trialPatrick J Grohar, Rachel Heise, Mary Frances Wedekind, et al.
American Journal of Medical Genetics. Part A|January 21, 2014
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapiesBrigitte C Widemann, Maria T Acosta, Sylvia Ammoun, et al.
Pageof 21

Showing results (191-200 of 203) with videos related to

Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2024
Update on Pediatric Cancer Surveillance Recommendations for Patients with Neurofibromatosis Type 1, Noonan Syndrome, CBL Syndrome, Costello Syndrome, and Related RASopathiesMelissa R Perrino, Anirban Das, Sarah R Scollon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2024
Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA FragmentomicsR Taylor Sundby, Jeffrey J Szymanski, Alexander C Pan, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 2, 2018
Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrumVictoria E R Parker, Kim M Keppler-Noreuil, Laurence Faivre, et al.
Neuro-Oncology|July 5, 2022
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensusPeter M K de Blank, Andrea M Gross, Srivandana Akshintala, et al.
American Journal of Medical Genetics. Part A|March 26, 2019
First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeuticsKatherine A Rauen, Abeer Alsaegh, Shay Ben-Shachar, et al.
American Journal of Medical Genetics. Part A|September 27, 2014
Update from the 2013 International Neurofibromatosis ConferenceScott R Plotkin, Anne C Albers, Dusica Babovic-Vuksanovic, et al.
Nature Medicine|January 14, 2021
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trialMichael J Fisher, Chie-Schin Shih, Steven D Rhodes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2023
The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric CancerJoseph A Flores-Toro, Subhashini Jagu, Gregory T Armstrong, et al.
Nature Medicine|April 16, 2026
Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trialPatrick J Grohar, Rachel Heise, Mary Frances Wedekind, et al.
American Journal of Medical Genetics. Part A|January 21, 2014
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapiesBrigitte C Widemann, Maria T Acosta, Sylvia Ammoun, et al.
Pageof 21